Not many people would regard the diagnosis of a serious autoimmune disorder as good news. But for Meredith Kass, 17, learning she had systemic lupus erythematosus was far preferable to her doctors’ original suspicion, lymphoma.
Kass, a senior at Kellenberg Memorial High School and a resident of Seaford, first suspected something was wrong two years ago. A member of her school’s cheerleading and varsity lacrosse squads, she had begun complaining of fatigue. “I was just tired and achy all the time,” she recalled.
ImmuPharma PLC (LON:IMM) is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.